These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 22052452

  • 1. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Fuerst T, Engelke K, Genant HK.
    J Bone Miner Res; 2012 Feb; 27(2):255-62. PubMed ID: 22052452
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bone mineral density changes following discontinuation of ronacaleret treatment: off-treatment extension of a randomized, dose-finding phase II trial.
    Fitzpatrick LA, Wooddell M, Dabrowski CE, Cicconetti G, Gordon DN.
    Bone; 2014 Oct; 67():104-8. PubMed ID: 24794093
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial.
    Fitzpatrick LA, Smith PL, McBride TA, Fries MA, Hossain M, Dabrowski CE, Gordon DN.
    Bone; 2011 Oct; 49(4):845-52. PubMed ID: 21742071
    [Abstract] [Full Text] [Related]

  • 6. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study.
    Takahashi R, Chiba K, Okazaki N, Era M, Yokota K, Yabe Y, Kondo C, Fukuda T, Fukushima K, Kono M, Michikoshi Y, Yamada S, Iida T, Mitsumizo K, Sato S, Doi M, Watanabe K, Ota S, Shiraishi K, Yonekura A, Osaki M.
    Bone; 2024 Oct; 187():117189. PubMed ID: 38960296
    [Abstract] [Full Text] [Related]

  • 7. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
    Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C.
    J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
    [Abstract] [Full Text] [Related]

  • 8. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
    Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, de Papp A.
    J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
    [Abstract] [Full Text] [Related]

  • 9. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [Abstract] [Full Text] [Related]

  • 10. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 11. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 12. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.
    J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
    [Abstract] [Full Text] [Related]

  • 13. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2003 Sep 25; 349(13):1207-15. PubMed ID: 14500804
    [Abstract] [Full Text] [Related]

  • 14. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, Dardzinski B, Cabal A, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Bone Miner Res; 2014 Aug 25; 29(8):1786-94. PubMed ID: 24643905
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct 25; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 16. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
    Engelke K, Nagase S, Fuerst T, Small M, Kuwayama T, Deacon S, Eastell R, Genant HK.
    J Bone Miner Res; 2014 Mar 25; 29(3):629-38. PubMed ID: 24038152
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 25; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 18. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.
    Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA.
    Bone; 2010 Feb 25; 46(2):534-42. PubMed ID: 19786130
    [Abstract] [Full Text] [Related]

  • 19. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
    Ganapathy A, Nieves JW, Keaveny TM, Cosman F.
    Bone; 2023 Feb 25; 167():116618. PubMed ID: 36410666
    [Abstract] [Full Text] [Related]

  • 20. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C.
    Bone; 2010 Jul 25; 47(1):131-9. PubMed ID: 20399288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.